… a variety of advanced cancers, including melanoma, renal cell carcinoma, non-small cell lung
… new target for reduction of anti-PD-1 induced toxicity, while maintaining anti-tumor efficacy. …

… for the effects of a PD-1 blockade have not been identified, an … enhanced in a mouse model
of renal cell carcinoma [58]. … variety of immune-mediated toxicities, including hepatitis, small …

… immunotherapy by modulating pathways such as PD-1/PDL-1… canal and rapidly eliminated
by the kidney (11). The original … Among these targets, the mitochondrial uncoupling function …

… for high-efficacy, low-toxicity therapeutic options [35]. … burden reduction in pancreatic cancer,
renal cell carcinoma, and … infiltration and thus improve the efficacy of anti-PD-1 therapy [251]…

… to the approval of antibodies targeting PD-1 or PD-L1 for the … to disentangle its toxicity
from its efficacy and amplify its … assess the efficacy and molecular correlates of kidney cancer …

… T-cell activation, interferon pathways, PD-1 signaling and T-cell … We focused on signatures
uncoupled from avelumab treatment … Intriguingly, a case report of a renal allograft patient with …

… compare the toxicity resulting from the use of anti–PD-1 and anti… Effectiveness of
immunotherapy is also determined by … in the course of immunosuppression after kidney (59%), …

… programmed cell death 1 (PD-1) or TIM-3 … toxicities and intratumoural penetration may be
challenging with systemic administration. Several clinical trials investigating safety and efficacy …

… with better graft function in kidney transplant recipients. In … transplantation, but are burdened
by significant toxicities, including … therapeutic strategies to uncouple anticancer and anti-…

… the use of anti-PD-1 without loss of the renal graft. We present a … and efficacy of immune
checkpoint inhibitors in kidney transplant … The data indicate that inhibition of the mTOR pathway …